

1 **Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection**  
2 **in long-term care facilities in Spain**

3 Susana Monge<sup>1</sup>, Carmen Olmedo<sup>2</sup>, Belén Alejos, María Fé Lapeña<sup>3</sup>, María José Sierra<sup>1\*</sup>,  
4 Aurora Limia<sup>2\*</sup> and the COVID-19 registries study group.

5 <sup>1</sup>Centre for the Coordination of Alerts and Health Emergencies, General Directorate of  
6 Public Health, Ministry of Health.

7 <sup>2</sup>Vaccines division, General Directorate of Public Health, Ministry of Health.

8 <sup>3</sup>Data analytics department, General Directorate of Digital Health and National Health  
9 Service Information Systems, Ministry of Health.

10 \* These persons contributed equally to this work.

11

12 **Conflicts of interest:** authors declare no support from any organisation for the  
13 submitted work; no financial relationships with any organisations that might have an  
14 interest in the submitted work in the previous three years, no other relationships or  
15 activities that could appear to have influenced the submitted work.

16

17 **Contributions:** SM, CO, MJS and AL conceived the idea for the study. SM and CO  
18 designed the analysis which was performed by SM with help from BA, support from  
19 MFL and under the supervision of MJS and AL. All authors participated in the  
20 interpretation of results and critically reviewed the content of the manuscript.

21

22 **Funding:** This work did not receive any specific grant from funding agencies in the  
23 public, commercial, or not-for-profit sectors.

24 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Members of the COVID-19 registries study group:** David Moreno, Manuel Méndez  
26 Díaz, Ismael Huerta González, Antonia M<sup>a</sup> Galmes Truyol, Ana Barreno Estévez,  
27 Valvanuz García Velasco, M<sup>a</sup> Jesús Rodríguez Recio, José Sacristán, Montserrat  
28 Martínez Marcos, Eliseo Pastor Villalba , María José Macías Ortiz, Ana García Vallejo,  
29 Sara Santos Sanz, Rocío García Pina , Aurelio Barricarte Gurea, Rosa Sancho Martínez,  
30 Eva María Ochoa, Mauricio Vázquez Cantero, Atanasio Gómez Anés, María Jesús  
31 Pareja Megía, Yolanda Castán, Manuel Roberto Fonseca Álvarez, Antonia Salvà Fiol,  
32 Hilda Sánchez Janáriz, Luz López Arce, María Ángeles Cisneros Martín, José Sacristán,  
33 Frederic Jose Gibernau, Cesar Fernandez Buey, Katja Villatoro Bongiorno, Francisco Javier  
34 Rubio García, Fernando Santos Guerra, Jenaro Astray Mochales, Francisco Javier  
35 Francisco Verdu, Isabel García Romero, Rosa Oriza Bernal, Tomás Gómez Pérez, Salomé  
36 Hijano Villegas, Sergio Román Soto, Virgilio Yagüe Galaup, Mercedes Alfaro Latorre,  
37 Marta Aguilera Guzmán, Belén Crespo Sánchez-Eznarriaga, Montserrat Neira León,  
38 Noemí Cívicos Villa.  
39

40 **Abstract**

41 **Objectives** To estimate indirect and total (direct plus indirect) effects of COVID-19  
42 vaccination in residents in long-term care facilities (LTCF).

43 **Design** Registries-based cohort study including all residents in LTCF  $\geq 65$  years offered  
44 vaccination between 27 December 2020 and 10 March 2021. Risk of SARS-CoV-2  
45 infection following vaccination was compared with the risk in the same individuals in a  
46 period before vaccination. Risk in non-vaccinated was also compared to a period  
47 before the vaccination programme to estimate indirect protection. Standardized  
48 cumulative risk was computed adjusted by previous documented infection (before the  
49 start of follow-up) and daily-varying SARS-CoV-2 incidence and reproductive number.

50 **Participants** 573,533 records of 299,209 individuals in the National vaccination registry  
51 were selected; 99.0% had  $\geq 1$  vaccine-dose, 99.8% was Pfizer/BioNTech (BNT162b2).  
52 Residents mean age was 85.9, 70.9% were females. A previous SARS-CoV-2 infection  
53 was found in around 25% and 13% of participants, respectively, at the time of vaccine  
54 offer and in the reference period.

55 **Main outcome measures** Documented SARS-CoV-2 infection identified in the National  
56 COVID-19 laboratory registry.

57 **Results** Total VE was 57.2% (95% Confidence Interval: 56.1%-58.3%), and was highest  
58  $\geq 28$  days after the first vaccine-dose (*proxy* of  $\geq 7$  days after the second dose) and for  
59 individuals naïve to SARS-CoV-2 [81.8% (81.0%-82.7%)] compared to those with  
60 previous infection [56.8% (47.1%-67.7%)]. Vaccination prevented up to 9.6 (9.3-9.9)  
61 cases per 10,000 vaccinated per day; 11.6 (11.3-11.9) if naïve vs. 0.8 (0.5-1.0) if  
62 previous infection. Indirect protection in the non-vaccinated could only be estimated

63 for naïve individuals, at 81.4% (73.3%-90.3%) and up to 12.8 (9.4-16.2) infections  
64 prevented per 10,000 indirectly protected per day.

65 **Conclusions** Our results confirm the effectiveness of mRNA vaccination in  
66 institutionalized elderly population, endorse the policy of universal vaccination in this  
67 setting, including in people with previous infection, and suggest that even non-  
68 vaccinated individuals benefit from indirect protection.

69 **Key-words:** COVID-19; SARS-CoV-2; vaccination; vaccine effectiveness; long-term care  
70 facilities; elderly; indirect effects.

71

72 **Key messages:**

- 73 • COVID-19 vaccination reduced the risk of documented SARS-CoV-2 infection in  
74 institutionalized elderly by 57.2% (56.1% to 58.3%), which increased to 81.2%  
75 (80.2% to 82%) for the fully vaccinated.
- 76 • In individuals naïve to SARS-CoV-2 vaccination reduced the risk by up to 81.8% and  
77 averted up to 11.6 cases per 10,000 vaccinated persons per day.
- 78 • Those with previous infection also benefited from a risk reduction of 57%, which  
79 translated in less than 1 infection averted per 10,000 vaccinated persons per day.
- 80 • Non-vaccinated individuals living in facilities where the majority (residents and  
81 staff) had been vaccinated showed a risk reduction similar to those actually  
82 vaccinated.

83

84 **MAIN TEXT**

85 **Introduction**

86 Since the beginning of the COVID-19 pandemic up to March 7 2021, 18,927 residents in  
87 long-term care facilities (LTCF) have died in Spain with confirmed COVID-19, and an  
88 additional 10,492 have died with compatible symptoms [1]. This means a cumulative  
89 mortality rate of 67 per 1,000 residents, accounting only for confirmed infections. This  
90 high vulnerability is due to the higher risk of exposure in dependents living in a closed  
91 institution but also to the higher severity of infection due to advanced age and  
92 presence of comorbidities. Indeed, one on every 5 cases of SARS-CoV-2 infection died  
93 in this setting [1].

94 COVID-19 vaccination in Spain started on December 27 with the Pfizer/BioNTech  
95 (BNT162b2) vaccine, for which LTCF -both residents and workers- were the first priority  
96 group [2]. The vaccination campaign coincided with the third COVID-19 epidemic wave,  
97 with national 14-day cumulative incidence increasing from less than 250 cases per  
98 100,000 population by the end of 2020 to more than 1,000 by the end of January 2021  
99 [3]. Vaccination started in facilities considered at higher risk, such as those that had  
100 never experienced a COVID-19 outbreak, had higher number of residents or more  
101 difficulties for implementing prevention and control measures. Vaccination teams  
102 visited the facilities and vaccination was universal, including those with previous SARS-  
103 CoV-2 infection. Vaccination was only deferred in people with active infection and,  
104 inconsistently, in people under quarantine. Acceptance has been very high, with 97.8%  
105 of all institutionalized persons (any institution type) having received at least one  
106 vaccine dose, and 88.8% two doses [4].

107 The Pfizer/BioNTech vaccine has shown an efficacy of 95% in preventing Covid-19 in  
108 randomized clinical trials [5]. However, elderly persons in general, and those  
109 institutionalized in particular, are not represented in randomized studies [6]. Therefore  
110 there is great interest in estimating vaccine effectiveness (VE) in this population  
111 following its widespread vaccination. Moreover, because vaccination coverage was so  
112 high, it is expected that non-vaccinated persons could be indirectly protected if  
113 vaccination reduces infection and transmissibility among vaccinated persons. A few  
114 observational studies focusing on the elderly have been published in the last weeks  
115 [7,8]; one published and two pre-print studies have specifically addressed vaccine  
116 effects in LTCF residents [9,10,11], and none have tried to address the indirect  
117 protection in non-vaccinated individuals in this high-coverage setting.  
118 This study aims to estimate indirect and total (direct plus indirect) effects of  
119 vaccination in residents in LTCF in a high incidence context.

## 120 **Methods**

### 121 *Data sources*

122 REGVACU is a nation-wide registry of all COVID-19 vaccine-doses administered and  
123 vaccine rejections. Data was extracted on March 15 and the administrative censoring  
124 date was March 10. Individuals  $\geq 65$  years of age by December 27, with a valid postal  
125 code, and identified as “resident in elderly homes” according to REGVACU were  
126 selected. SERLAB is a nation-wide registry of all SARS-CoV-2 PCR and rapid antigenic  
127 tests performed. Positive tests within 60 days of a previous positive one were dropped,  
128 as they were considered to belong to the same episode. In LTCF, tests were performed  
129 to symptomatic persons and risk contacts. Incoming residents were also routinely  
130 tested and periodical screenings have also been carried out. Therefore, documented

131 infections registered in SERLAB may correspond both to symptomatic and  
132 asymptomatic infections, although this circumstance was not recorded in the system.  
133 Residents in REGVACU were cross-matched with SERLAB by person identification  
134 number, date of birth and sex.

### 135 *Study design*

136 To estimate the total (direct and indirect) effect of vaccination in vaccinated  
137 individuals, the risk of SARS-CoV-2 documented infection in the cohort of individuals  
138 with the first dose administered between December 27 and March 10 was compared to  
139 the risk in the same individuals in a period before the start of the vaccination  
140 programme. A before-after comparison was deemed more appropriate since, due to  
141 the high vaccination coverage at LTCFs, non-vaccinated individuals after December 27  
142 would probably not represent baseline infection risk had the individual not been  
143 vaccinated. Baseline infection risk, on the other hand, is heavily influenced by  
144 community incidence and the vaccination campaign coincided with the third epidemic  
145 wave in Spain. To minimize this effect the second epidemic wave was chosen as  
146 comparison period, starting the follow-up of the non-vaccinated period 87 days before  
147 individual-specific first dose administration date (October 1, at the earliest), with  
148 administrative censoring on December 13, 87 days before March 10 (supplementary  
149 Figure S1).

150 To estimate the indirect protection of vaccination in not vaccinated individuals, the risk  
151 of SARS-CoV-2 documented infection in the cohort of individuals never vaccinated  
152 between December 27 and March 10 was compared to the risk in the same individuals  
153 87 days before, similarly as previously explained for vaccinated individuals. The follow-  
154 up period started at the earliest date when the vaccine was offered to each individual,

155 since all residents at the same LTCF were offered vaccination on the same day.  
156 Therefore individuals were ensured to be included on the date that a first vaccine-dose  
157 was administered to most of the co-residents and workers.

158 The follow-up for all individuals finished at the earliest of a SARS-CoV-2 positive test or  
159 administrative censoring. Unfortunately, no information on the individuals' vital status  
160 was available. Existence of any previous SARS-CoV-2 documented infection on the first  
161 day of follow-up was also registered.

162 An additional analysis to investigate the possible design-associated bias is presented in  
163 the supplementary material.

164 The study obtained approval from the research ethics committee at the Instituto de  
165 Salud Carlos III (CEI PI 98\_2020). Patients or the public were not involved in the design, or  
166 conduct, or reporting, or dissemination plans of our research. Results of this study are  
167 planned to be disseminated to the broad public.

#### 168 *Data analysis*

169 The standardized cumulative risk of a documented SARS-CoV-2 infection that every  
170 individual had in the sample been either vaccinated or not vaccinated was computed  
171 [12]. To estimate the probability of the event on each follow-up day, conditioned to  
172 remaining event-free up to that day and given the individual covariates, a pooled  
173 logistic regression was fitted adjusting by follow-up day, previous SARS-CoV-2 infection  
174 (before beginning of follow-up), daily-varying 7-day SARS-CoV-2 cumulative incidence  
175 specific to the province, its quadratic term, and the empirical reproduction number for  
176 that province on that date. An interaction between follow-up day and vaccination was  
177 introduced to allow for a time-varying effect of the vaccine. Robust models were built  
178 using individuals as clusters. Standardized cumulative risk curves were derived using

179 the Kaplan-Meier method. Risk ratios (RR), vaccine effectiveness (VE= 1-RR) and risk  
180 difference (RD) were estimated for the overall period and in four sub-periods after the  
181 administration of the first dose, as proxies of different vaccine protection: (1) 14 days;  
182 (2) 14 to 21 days; (3) 21 to 28 days (proxy of first 7 days after the second dose) and; (4)  
183 >28 days (proxy of fully vaccinated, i.e.  $\geq 7$  days after second vaccine dose). Normal  
184 distribution-based confidence intervals were estimated using bootstrapping with 300  
185 repetitions.

## 186 **Results**

### 187 *Description of participants*

188 Out of 5,068,733 vaccination records from 3,615,403 individuals in REGVACU, 573,533  
189 records from 299,209 individuals were selected; 296,093 (99.0%) had received  $\geq 1$   
190 vaccine-dose, of which 99.8% were Pfizer/BioNTech (BNT162b2) and 0.2% Moderna  
191 vaccine; 92.6% of them received a second vaccine-dose in a median of 21 days  
192 (interquartile range: 21-21). Time to vaccination is shown in supplementary figure S2.  
193 Mean age was 85.9 years (standard deviation = 7.8) and 70.9% were females. Selected  
194 individuals were cross-matched with SERLAB; 77,662 (26.0%) had at least one positive  
195 test between March 1, 2020 and March 11, 2021. A SARS-CoV-2 previous infection was  
196 found in 17.5% of participants on the date they started the follow-up for the total  
197 effects study; 22.3% in the vaccinated group and 12.7% in the comparison group (from  
198 87 days before). In the indirect effects analysis, 20.3% had previous infection; 27.7% in  
199 the indirectly protected and 12.9% in the comparison group.

### 200 *Estimation of vaccine effectiveness in vaccinated persons*

201 This analysis included 16,277,284 and 16,142,536 person-days of follow-up among  
202 vaccinated and non-vaccinated persons, respectively. There were 11,304 and 19,656

203 documented infections, respectively (supplementary table S1). Detailed information on  
204 the crude estimates and adjusted cumulative risk in each group can be found in the  
205 supplementary material (Figure S3 and Tables S2 and S3).

206 Vaccine effectiveness for the whole study period was 57.2% (95% Confidence Interval:  
207 56.1% to 58.3%), but it increased after two vaccine doses, and was higher in individuals  
208 without previous SARS-CoV-2 infection; VE was 81.8% (81.0% to 82.7%) for residents  
209 fully vaccinated and with no previous infection, but decreased to 56.8% (47.1% to  
210 67.7%) if previous infection (Table 1, Figure 1). Interestingly, in a separate analysis we  
211 found that previous infection in the reference period was associated to a risk reduction  
212 of 86.6% (85.2%-87.8%), higher than the estimate for complete vaccination.

213 The estimated number of SARS-CoV-2 infections averted by vaccination (risk  
214 difference) was greatest in the intermediate periods, which coincided with the peak of  
215 the epidemic waves, at 11.6 cases per 10,000 vaccinated persons per day in the group  
216 without previous infection (Table 1). In the group with previous infection, the number  
217 of infections averted was much lower, of around 0.6 – 0.7 per 10,000 vaccinated  
218 persons per day.

#### 219 *Estimation of indirect vaccine effectiveness in non-vaccinated persons*

220 This analysis included 164,520 and 161,388 person-days of follow-up, respectively,  
221 among persons not vaccinated but who had been offered the vaccine at their LTCF  
222 (indirectly protected) and same persons in the reference period (87 days before).  
223 There were 126 and 276 events, respectively (supplementary Table S1). Detailed  
224 information on the crude estimates and the adjusted cumulative risk in each group can  
225 be found in the supplementary material (Figure S3 and Tables S2 and S3).

226 Indirect protection was estimated at 57.3% (48% to 66.3%) for the whole study-period.  
227 There was no statistically significant reduction in risk in the first 14 days of follow-up  
228 but it increased progressively thereafter, particularly after 28 days (as a proxy of full  
229 immunization of vaccinated persons at the LTCF), when VE reached 79.5% (71.0% to  
230 88.1%) overall and 81.4% (73.3% to 90.3%) for the group with no documented SARS-  
231 CoV-2 infection before the beginning of follow-up (Table 1, Figure 1).

232 The estimated number of SARS-CoV-2 infections averted by vaccination was similar to  
233 the one found in the vaccinated group for individuals without previous infection, of 11  
234 .0 and 12.8 per 10,000 non-vaccinated persons per day in the intermediate periods  
235 (Table 1).

236 It was not possible to estimate VE for indirect protection in the group with a previous  
237 SARS-CoV-2 infection since there were only 14 events, confidence intervals virtually  
238 tended to infinite, and the model did not result in credible risk curves.

## 239 **Discussion**

240 This study on the institutionalized elderly confirms the high benefit of vaccination in  
241 this population, reducing the risk of infection by up to 81.2% and avoiding up to 9.6  
242 cases per 10,000 population per day. The risk reduction was through direct protection  
243 of those vaccinated but also through indirect protection of those who were not-  
244 vaccinated. The vaccine effectiveness increased throughout the study period, likely  
245 showing the progressive immunization of vaccinated persons with increasing time  
246 elapsed since the first-dose and after the receipt of the second dose. While VE was  
247 higher for individuals naïve to SARS-CoV-2, those with previous infection also benefited  
248 from vaccination, even the absolute gain in number of infections averted was low,  
249 possibly due to an already lower baseline risk in this group.

250 Immunesenescence and factors related to chronic conditions, together with  
251 malnutrition, are known to impair immunity required for an effective vaccine response  
252 [13], and lower neutralizing antibodies response to Pfizer/BioNTech vaccine in people  
253  $\geq 65$  years has been reported [6,14]. However, our estimates resulted fairly similar to  
254 those of observational studies in younger adult population and are consistent with  
255 other studies showing high VE in the elderly from the general population. A cohort of  
256 health care workers in the UK found a VE of 70% 21 days after the first dose and of  
257 85% 7 days after the second dose of Pfizer/BioNTech [15]. A slightly higher estimate, of  
258 94.1%, is given by a pre-print with data from Israel [16]. Other observational studies  
259 have explored VE in older age groups. In a registries-based study from Israel, in  
260 persons aged  $\geq 70$  years, VE was found to be 44%, 64% and 98% at 14-20 days post-  
261 vaccination, 21-27 days post-vaccination and  $\geq 7$  days after the second vaccine-dose,  
262 respectively, which were similar to the results for younger age groups [17]. Bernal et al  
263 have reported vaccine effects to start 10-13 days after vaccination with  
264 Pfizer/BioNTech and reach 61% in people aged  $\geq 70$  years and 70% in people aged  $\geq 80$   
265 years  $\geq 28$  days post-vaccination, and 89% 14 days after the second vaccine-dose [8].  
266 A study in LTCF in Connecticut experiencing COVID-19 outbreaks found a 63%  
267 protection with partial vaccination (between 14 and 28 days of the first dose), close to  
268 our estimates, with unchanged results after excluding those with previous infection  
269 [9]. However, two other existing studies focusing on LTCF have reported lower VE. A  
270 Danish study in pre-print [10], has found no protective effect of a first vaccine-dose, a  
271 52% reduction in days 0-7 after the second dose and 64% beyond day 7. A recently  
272 released pre-print manuscript from the VIVALDI study in the UK has found no  
273 protection conferred by vaccination with the Pfizer/BioNTech vaccine in the first 28

274 days after the first dose [11]. Nevertheless, VE between days 28 to 47 was between  
275 56% and 62% [11], in a similar range of the effect found in this study for the period 22-  
276 28 days (61.9%). Early results from British Columbia have estimated 80% reduction in  
277 risk 2-3 weeks after the first vaccine-dose [18]. Of note, our work included both  
278 symptomatic and asymptomatic infections, pointing that risk was probably reduced for  
279 both type of endpoints to an unknown degree. As an illustration, in national COVID-19  
280 surveillance, 39% of all notified infections since 10 May 2020 in people  $\geq 65$  years of  
281 age were asymptomatic.

282 A considerable 22% of all participants in our study had a previous documented SARS-  
283 CoV-2 infection, although there are possibly a high number of infections that were not  
284 documented, especially during the first epidemic wave in March-April 2020. Several  
285 studies have documented a high immune response to a first COVID-19 vaccine-dose in  
286 people with previous infection [19,20,21]. The results of this study add to previously  
287 existing literature that, even though the effect was greater in naïve subjects to SARS-  
288 CoV-2, those with previous infection also benefited from a risk reduction of 57%,  
289 although it translated in less than 1 infection averted per 10,000 population per day.

290 Results from the indirect protection analysis support the hypothesis that vaccination  
291 may reduce transmissibility of SARS-CoV-2 and result in herd immunity. Previous  
292 studies have shown decreased viral load in vaccinated patients, including those in LTCF  
293 [9, 22], and a study from Scotland found a 30% lower risk of SARS-CoV-2 in household  
294 members of vaccinated health-care workers, although the reduction in SARS-CoV-2  
295 transmission from vaccinated individuals could be double that estimate, since  
296 household members could also have been infected in the community [23]. A recent  
297 ecological study from Israel has shown that increasing vaccine coverage provides cross-

298 protection to unvaccinated individuals in the community [24]. In our study, non-  
299 vaccinated individuals living in facilities where the majority (residents and staff) had  
300 been vaccinated showed a risk reduction similar to those actually vaccinated.  
301 However, the magnitude of protection may be overestimated, since non-vaccinated  
302 individuals could correspond more frequently to persons with previous infection, even  
303 if not documented. This could be controlled in individuals with documented infection  
304 but not in an unknown number with non-documented infection or diagnosed with  
305 serology. Also, indirect protection was measured in a context of very high vaccine  
306 coverage, difficult to attain in a non-institutional setting; therefore our results may not  
307 have generalisability to the community setting.

308 Some limitations to study results could relate to the before-after comparison. Even  
309 though we tried to minimize it, residual confounding due to higher incidence during  
310 the third epidemic wave and possibly, to the relaxation of the isolation of LTCF during  
311 the Christmas season, with higher number of day-outs and visits, may be present and  
312 could underestimate the protection of the vaccine. This underestimation of the effect  
313 of the vaccine could maybe explain that the effect of natural infection in the non-  
314 vaccinated group was found higher than the effect of the vaccine. The conservative  
315 direction of the possible bias is shown by the bias indicator analysis (supplementary  
316 material).

317 In conclusion, our results confirm the effectiveness of vaccination in institutionalized  
318 elderly population, endorse the policy of universal vaccination in this setting, including  
319 in people with previous infection, and suggest that even non-vaccinated individuals  
320 benefit from indirect protection. Further questions include the duration of protection

321 in this population and according to previous infection, and the severity of infection,  
322 which could not be measured in this study.

NOT PEER-REVIEWED

323 **Acknowledgements**

324 We would like to acknowledge the contribution of the General Directorate of Digital  
325 Health and National Health Service Information Systems and the General Sub-  
326 Directorate for Health Information (Ministry of Health, Spain) for their work in  
327 managing the registries in which this study was based, as well as in providing all the  
328 necessary IT support. We specially thank Miguel Hernán for his methodological advice  
329 and support in the design of the analysis as well as Luis Sanguiao for his support in  
330 implementing parallel computing. We acknowledge as well all the work of the  
331 professionals involved in the vaccination program and in managing the vaccination and  
332 laboratory registries from the Autonomous Communities.

NOT PEER-REVIEWED

## 333 **References**

- 334 [1] Instituto de Mayores y Servicios Sociales (Imserso). Actualización nº 2. Enfermedad  
335 por coronavirus (COVID-19) en Centros Residenciales. 7/3/2021. Available at:  
336 [https://www.imserso.es/InterPresent2/groups/imserso/documents/binario/inf\\_resid\\_](https://www.imserso.es/InterPresent2/groups/imserso/documents/binario/inf_resid_20210312.pdf)  
337 [20210312.pdf](https://www.imserso.es/InterPresent2/groups/imserso/documents/binario/inf_resid_20210312.pdf) (Accessed 31 March 2021)
- 338 [2] Grupo de Trabajo Técnico de Vacunación COVID-19, de la Ponencia de Programa y  
339 Registro de Vacunaciones 2 de diciembre 2020. Estrategia de vacunación frente a  
340 COVID19 en España. 2 de diciembre 2020. Available at:  
341 [https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/](https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_EstrategiaVacunacion.pdf)  
342 [covid19/docs/COVID-19\\_EstrategiaVacunacion.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_EstrategiaVacunacion.pdf) (Accessed 31 March 2021)
- 343 [3] Centro de Coordinación de Alertas y Emergencias Sanitarias. Ministry of Health of  
344 Spain. Actualización nº 335. Enfermedad por el coronavirus (COVID-19). 18.03.2021.  
345 Available at:  
346 [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/doc](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_335_COVID-19.pdf)  
347 [umentos/Actualizacion\\_335\\_COVID-19.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_335_COVID-19.pdf) (Accessed 31 March 2021)
- 348 [4] GIV COVID-19. Gestión Integral de la vacunación COVID. Ministry of Health of Spain.  
349 Informe de actividad 18 de marzo. Available at:  
350 [https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/doc](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Informe_GIV_comunicacion_20210318.pdf)  
351 [umentos/Informe\\_GIV\\_comunicacion\\_20210318.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Informe_GIV_comunicacion_20210318.pdf) (Accessed 31 March 2021)
- 352 [5] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and  
353 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec  
354 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.

- 355 [6] Prendki V, Tau N, Avni T, Falcone M, Huttner A, Kaiser L, et al. A systematic review  
356 assessing the under-representation of elderly adults in COVID-19 trials. BMC Geriatr.  
357 2020 Dec 20;20(1):538. doi: 10.1186/s12877-020-01954-5.
- 358 [8] Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the  
359 Biontech / Pfizer BNT162b2 COVID-19 vaccination. MedRxiv [Preprint] 2021. doi:  
360 10.1101/2021.03.03.21251066.
- 361 [7] Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination  
362 with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on  
363 symptomatic disease, hospitalisations and mortality in older adults in the UK : a test  
364 negative case control study. MedRxiv [Preprint] 2021.  
365 DOI:10.1101/2021.03.01.21252652.
- 366 [9] Britton A, Jacobs Slifka K, Edens Ch et al. Effectiveness of the Pfizer-BioNTech  
367 COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing  
368 COVID-19 Outbreaks — Connecticut, December 2020–February 2021. MMWR 2021;70:  
369 Early Release March 15.
- 370 [10] Moustsen-Helms IR, Emborg HD, Nielsen J, Nielsen KF, Krause TG, Mølbak H, et al.  
371 Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine  
372 in long-term care facility residents and healthcare workers – a Danish cohort study.  
373 MedRxiv [Preprint] 2021. doi: 10.1101/2021.03.08.21252200.
- 374 [11] Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine  
375 effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2  
376 infection in residents of Long-Term Care Facilities (VIVALDI study). MedRxiv [Preprint]  
377 2021. doi: 10.1101/2021.03.26.21254391.

- 378 [12] Hernán MA, Robins JM (2020). Causal Inference: What If. Boca Raton: Chapman &  
379 Hall/CRC. Available at: [https://www.hsph.harvard.edu/miguel-hernan/causal-](https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/)  
380 [inference-book/](https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/) (Accessed 31 March 2021).
- 381 [13] Fulop T, Pawelec G, Castle S, Loeb M. Immunosenescence and vaccination in  
382 nursing home residents. Clin Infect Dis. 2009 Feb 15;48(4):443-8. doi: 10.1086/596475.
- 383 [14] Walsh EE, Frenck RW, Falsey AR, \*Kitchin N, Absalon J, Gurtman A, et al. Safety  
384 and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England  
385 Journal of Medicine. 2020;383(25):2439-50.
- 386 [15] Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett et al. Effectiveness of  
387 BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in  
388 Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN  
389 Study). Available at SSRN: <https://ssrn.com/abstract=3790399> (Accessed 31 March  
390 2021)
- 391 [16] Haas EJ, Frederick JA, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Nationwide  
392 Vaccination Campaign with BNT162b2 in Israel Demonstrates High Vaccine  
393 Effectiveness and Marked Declines in Incidence of SARS-CoV-2 Infections and COVID-  
394 19 Cases, Hospitalizations, and Deaths. Available at:  
395 [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3811387](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3811387) (Accessed 31 March  
396 2021)
- 397 [17] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA  
398 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Feb 24.  
399 doi: 10.1056/NEJMoa2101765. Online ahead of print. PMID: 33626250
- 400 [18] Early findings show the first vaccine dose reduced the risk of COVID-19 by 80 per  
401 cent or more. Press release. February 19, 2021. Available at:

402 [http://www.bccdc.ca/about/news-stories/news-releases/2021/early-findings-show-](http://www.bccdc.ca/about/news-stories/news-releases/2021/early-findings-show-the-first-vaccine-dose-reduced-the-risk-of-covid-19-by-80-per-cent-or-more)  
403 [the-first-vaccine-dose-reduced-the-risk-of-covid-19-by-80-per-cent-or-more](#) (Accessed  
404 31 March 2021)

405 [19] Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, et al.  
406 Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected  
407 individuals. *The Lancet*. 2021;397(10279):1057-8.

408 [20] Saadat S, Tehrani ZR, Logue J, \*Newman M, Frieman MB, Harris AD, et al. Single  
409 Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. medRxiv  
410 [Preprint] 2021. doi: 10.1101/2021.01.30.21250843.

411 [21] Camara C Lozano-Ojalvo D, Lopez-Granados E. Differential effects of the second  
412 SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered  
413 individuals. *Biorxiv* [Preprint] 2021. doi: 10.1101/2021.03.22.436441.

414 [22] Petter E, Mor O, Zuckerman N, Oz-Levi D, Younger A, Aran D, Erlich Y. Initial real  
415 world evidence for lower viral load of individuals who have been vaccinated by  
416 BNT162b2. *MedRxiv* [Preprint] 2021. doi: 10.1101/2021.02.08.21251329 .

417 [23] Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of  
418 vaccination on transmission of COVID-19: an observational study in healthcare workers  
419 and their households. *MedRxiv* [Preprint] 2021. doi: 10.1101/2021.03.11.21253275.

420 [24] Milman O, Noga Aharony IY, Katz R, Herzal E, Ben-Tov A, Kuint J, et al. SARS-CoV-2  
421 infection risk among unvaccinated is negatively associated with community-level  
422 vaccination rates. *MedRxiv* [Preprint] 2021. doi: 10.1101/2021.03.26.21254394.


423

424 **Table 1. Vaccine effectiveness (VE) and risk difference (RD) in residents of elderly long-term care facilities according to evidence of previous**  
 425 **infection and time since first vaccinated (as a proxy of number of vaccine - doses and days since last dose).**

		VACCINE EFFECTIVENES (%)			RISK DIFFERENCE (per 10,000 persons per day)		
		Overall	No previous infection	Previous infection	Overall	No previous infection	Previous infection
<b>EFFECTS IN THE VACCINATED</b>	Full period	57.2% (56.1% to 58.3%)	57.6% (56.6% to 58.6%)	36.3% (27.9% to 45.5%)	-6.26 (-6.45 to -6.06)	-7.37 (-7.58 to -7.16)	-0.64 (-0.86 to -0.44)
	Days 0-14	28.5% (26.4% to 30.7%)	28.9% (26.9% to 31%)	9.6% (-6.9% to 26.8%)	-5.06 (-5.52 to -4.57)	-6.05 (-6.56 to -5.54)	-0.25 (-0.72 to 0.23)
	Days 15-21	51.0% (49.7% to 52.3%)	51.9% (50.7% to 53.1%)	25.5% (15.1% to 36.6%)	-9.62 (-9.97 to -9.23)	-11.59 (-12.01 to -11.19)	-0.66 (-1.00 to -0.32)
	Days 22-28	61.9% (60.8% to 63%)	62.9% (61.9% to 64%)	34.6% (25.7% to 44.1%)	-9.65 (-9.92 to -9.35)	-11.59 (-11.92 to -11.28)	-0.76 (-1.03 to -0.5)
	Days ≥29	81.2% (80.2% to 82%)	81.8% (81.0% to 82.7%)	56.8% (47.1% to 67.7%)	-5.59 (-5.76 to -5.41)	-6.47 (-6.66 to -6.28)	-0.75 (-0.98 to -0.53)
<b>INDIRECT EFFECTS</b>	Full period	57.3% (48% to 66.3%)	58.7% (49.4% to 68.5%)	NA	-8.13 (-10.13 to -5.98)	-10.08 (-12.62 to -7.52)	NA
	Days 0-14	18.8% (-1.7% to 39.9%)	18.2% (-3.1% to 39.8%)	NA	-3.31 (-7.29 to 0.79)	-3.79 (-8.54 to 1.14)	NA
	Days 15-21	43.6% (31.3% to 55.5%)	45% (32.8% to 57.1%)	NA	-8.8 (-11.95 to -5.48)	-11.02 (-14.88 to -6.99)	NA
	Days 22-28	55.8% (45.2% to 65.9%)	57.8% (47.5% to 68.2%)	NA	-10.06 (-12.66 to -7.30)	-12.81 (-16.16 to -9.39)	NA
	Days ≥29	79.5% (71.0% to 88.1%)	81.4% (73.3% to 90.3%)	NA	-9.22 (-11.56 to -6.73)	-11.46 (-14.39 to -8.6)	NA

426 NA: The model did not result in plausible bias-free risk curves, therefore no estimations were drawn.

427 **Figure 1. Cumulative incidence of documented SARS-CoV-2 infection in residents in long-term care facilities estimated from adjusted hazards**  
 428 **models.**



429